* The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing

    capacity and increased automation helping to improve laboratory workflows
    and advance patient care.
  * The new cobas c 703 analytical unit offers industry-leading high throughput

clinical chemistry testing(1 )with up to 2,000 tests per hour and 70 reagent

    positions, doubling the existing clinical chemistry throughput on cobas pro
    integrated solutions.
  * The new cobas ISE neo analytical unit delivers more efficient ISE testing,
    reducing hands-on time through automated maintenance.

Basel, 24 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the
launch of its new analytical units, cobas® c 703 and cobas® ISE neo, for the
cobas® pro integrated solutions, in countries accepting the CE mark. The cobas
pro integrated solutions is a scalable and modular diagnostic platform designed
for high-volume laboratories. The cobas c 703 and cobas ISE neo analytical units
offer cutting-edge features to help address some of the key challenges faced by
diagnostic laboratories worldwide such as shortage of qualified staff and space
limitations.
"Today more than ever, accurate and timely diagnostics is critical for effective
delivery of healthcare. Labs are under increasing pressure to process more
samples, at greater speed without compromising on accuracy," said Matt Sause,
CEO of Roche Diagnostics."With the launch of the cobas c 703 and cobas ISE neo,
we are taking our latest generation clinical chemistry and immunochemistry
platform, the cobas pro integrated solutions, to the next level. By integrating
high-volume clinical chemistry testing and increased automation, we will set a
new standard for high volume testing in the clinical lab."
cobas c 703 analytical unit
The new cobas c 703 analytical unit is designed to double the clinical chemistry
throughput on cobas pro integrated solutions, offering up to 2,000 tests per
hour and 70 reagent positions. This increased onboard reagent capacity means
more high-value tests can be performed whilst improving workflow efficiency and
saving time spent reloading reagents. This new unit will minimise operator
maintenance to once a month, increasing uptime for laboratories.
cobas ISE neo analytical unit
The cobas ISE neo is designed to improve ion selective electrode (ISE) testing
efficiency, offering up to 1,800 tests per hour. With a number of innovative
hardware and software features, including an automated calibration concept, it
significantly reduces the need for manual intervention. It also performs more
tests per reagent bottle, reducing the frequency of bottle changes, minimising
plastic waste, and reducing logistical efforts compared to previous generation
systems.
By automating work that would have been done manually in the past, these new
units further improve lab efficiency, thus addressing the shortage of qualified
staff and increasing the volume of tests that can be delivered to the people who
need them most.
About cobas pro integrated solutions
Launched in 2018, cobas pro integrated solutions is a scalable and modular
solution designed to meet mid-to-very-high volume clinical chemistry and
immunochemistry testing needs. It aims to increase efficiency with fast
analytical units, intelligent sample routing, and short assay incubation times,
with 93% of Roche immunoassays having reaction times of 18 minutes or less.(2)
This analyser features automated maintenance and cobas® AutoCal, an automated
calibration procedure, to save hands-on time. Additionally, it incorporates
cobas® SonicWash, an ultrasonic probe cleaning to ensure sample integrity.
cobas pro integrated solutions provides fully standardised results and operation
to cobas® pure integrated solutions. Together, they deliver a seamless
experience and the highest level of standardisation using the same reagents and
assay menu, delivering consistent results and operation, and therefore allowing
for flexible staff assignment and minimal training needs. This also makes the
systems ideal candidates for integrated health networks and lab chains.
cobas pro integrated solutions is fully compatible with the cobas® mobile
solution, a tablet that integrates multiple Roche applications, allowing
laboratory professionals to interact with the analyser from anywhere in the lab.
With cobas pro integrated solutions, the required sample volume per test has
been reduced on average by 43% compared to previous generation systems.(3)
Additionally, the plastic generated per test result has been reduced by up to
78% due to smaller reagent pack sizes and a higher number of tests per pack.(4)
Designed to seamlessly integrate into clinical chemistry and immunochemistry
testing, Roche's innovative mass spectrometry analyser will also be available as
part of the cobas pro integrated solutions in the near future.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial
manufacturers of branded medicines, Roche has grown into the world's largest
biotechnology company and the global leader in in-vitro diagnostics. The company
pursues scientific excellence to discover and develop medicines and diagnostics
for improving and saving the lives of people around the world. We are a pioneer
in personalised healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care for each
person we partner with many stakeholders and combine our strengths in
Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do,
Roche has been named one of the most sustainable companies in the
pharmaceuticals industry by the Dow Jones Sustainability Indices for the
fifteenth consecutive year. This distinction also reflects our efforts to
improve access to healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com (http://www.roche.com).
All trademarks used or mentioned in this release are protected by law.
References
(1) Internal data on file
(2) Roche cobas e 801 Immunochemistry Assay Method Sheets
(3) Reduction is a comparison to cobas c 501 module, part of cobas® 6000
analyser series
(4) Reduction is a comparison to cobas e 601 module, part of cobas® 6000
analyser series
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
(mailto:media.relations@roche.com)

  Hans Trees, PhD           Sileia Urech
  Phone: +41 79 407 72 58   Phone: +41 79 935 81 48
  Nathalie Altermatt        Simon Goldsborough
  Phone: +41 79 771 05 25   Phone: +44 797 32 72 915
  Karsten Kleine            Nina Mählitz
  Phone: +41 79 461 86 83   Phone: +41 79 327 54 74
  Kirti Pandey              Yvette Petillon
  Phone: +49 172 6367262    Phone: +41 79 961 92 50
  Dr. Rebekka Schnell
  Phone: +41 79 205 27 03

Roche Investor Relations

 Dr. Bruno Eschli                        Dr. Sabine Borngräber
 Phone: +41 61 68-75284                  Phone: +41 61 68-88027
 e-mail: bruno.eschli@roche.com          e-mail: sabine.borngraeber@roche.com
 (mailto:bruno.eschli@roche.com)         (mailto:sabine.borngraeber@roche.com)
                                          (mailto:sabine.borngraeber@roche.com)

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
(mailto:birgit.masjost@roche.com)
Investor Relations North America

  Loren Kalm
  Phone: +1 650 225 3217
  e-mail: kalm.loren@gene.com (mailto:kalm.loren@gene.com)

Â